Post

New research · Internal Medicine
Heart & lung : the journal of critical care · 3h
Cohort studyHeart & lung : the journal of critical care · 2026

Anticoagulation strategies and pulmonary safety in patients with active lung cancer and atrial fibrillation: A large-scale, competing risk analysis of 2000 patients.

Ersin Kaya, Tarık Şimşek, İnan Mutlu
Read paper
Internal MedicineCohort study

Direct Oral Anticoagulants linked to less massive hemoptysis than vitamin K antagonists in lung cancer

Anticoagulation strategies and pulmonary safety in patients with active lung cancer and atrial fibrillation: A large-scale, competing risk analysis of 2000 patients.

Ersin Kaya … İnan Mutlu
Heart & lung : the journal of critical care · 2026
Background

Active lung cancer induces a profound hypercoagulable state.

Purpose

We aimed to evaluate the efficacy-safety trade-off of various anticoagulation strategies and quantify the clinical impact of the "treatment gap" in patients with active lung cancer and comorbid atrial fibrillation (atrial fibrillation).

Methods

This retrospective observational study analyzed 2000 patients with active lung cancer and atrial fibrillation (2018-2025).

n = 2000 patients
Results

massive bleeding was far less common with Direct Oral Anticoagulants than with Vitamin K Antagonists

sHR 0.42 (95% CI 0.24 to 0.72)
null = 00.240.72
CI excludes the null - significant
More results

The untreated cohort (12.7%) exhibited a 13.3% annual ischemic stroke rate.

In Inverse Probability of Treatment Weighting-adjusted analysis, Direct Oral Anticoagulants significantly reduced ischemic stroke risk compared to Vitamin K Antagonists (sHR: 0.42; 95% CI: 0.24-0.72; P = 0.002).

More results

Squamous cell histology significantly interacted with Vitamin K Antagonists use, exacerbating pulmonary bleeding risk (P-interaction=0.002).

“
Conclusion · 1 of 3

Direct Oral Anticoagulants offer a superior efficacy-safety profile over Vitamin K Antagonists in patients with active lung cancer and atrial fibrillation.

Conclusion · 2 of 3

The substantial treatment gap observed underscores a high, preventable stroke burden driven by clinical apprehension.

Conclusion · 3 of 3

Direct Oral Anticoagulants-based anticoagulation is a viable, safer strategy even in high-risk thoracic oncology phenotypes.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Cohort Study
4.5 minutes
Each visual-field test averaged 4.5 minutes per eye.
Review
46.7%
nearly half of thyroid patients had Graves' disease, the most common overactive-thyroid condition
Cross-sectional
MYR 88,346.12
Average annual out-of-pocket expenditure for patients with cancer in Malaysia.
Case-control
5.4% Reduction in Odds of Neuropathy
each rise in zinc levels lowers the chance of nerve damage
Cross-sectional
SIR 9.93
risk climbs sharply when relatives cluster and clotting starts young
Cohort Study
67.8%
one-year survival was far worse than the intermediate-risk group's, roughly one in three died
Systematic Review
“Current evidence does not support universal thromboprophylaxis following ACLR.”